Insights

BARD1 (ASX:BD1) share price ends stellar day up 41%

BARD1 had a fantastic day…
The post BARD1 (ASX:BD1) share price ends stellar day up 41% appeared first on The Motley Fool Australia. –

The BARD1 Life Sciences Ltd (ASX: BD1) share price was a very strong performer on Friday.

At one stage, the diagnostics company’s shares were up as much as 44% to $1.43.

The BARD1 share price gave back some of these gains but ultimately ended the day 41% higher at $1.40.

Why did the BARD1 share price rocket higher?

Investors were bidding the BARD1 share price higher today following the release of an update on a patent.

According to the release, US Patent No: 11137402 titled “Lung Cancer Diagnosis” has been issued by the United States Patent and Trademark Office.

The issued patent covers methods for detecting antibodies to BARD1 peptides, methods for diagnosing lung cancer, and kits for lung cancer diagnosis.

It certainly has been a long time coming. The release explains that patent application was filed in November 2014 and will be active until February 2035. This gives BARD1 plenty of time to seek to monetise the technology in the massive US market.

BARD1’s CEO, Dr Leearne Hinch, appeared to be pleased with the news.

She said: “This patent family enforces intellectual property protection in the US for a potential BARD1-Lung cancer test that detects autoantibodies associated with lung cancer.”

What is BARD1?

BARD1 describes itself as an Australian diagnostics company with an innovative portfolio of diagnostic technologies and products.

It is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. The company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.

In addition, it has a cancer diagnostic pipeline which includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

The BARD1 share price has now more than doubled in value in 2021.

The post BARD1 (ASX:BD1) share price ends stellar day up 41% appeared first on The Motley Fool Australia.

Should you invest $1,000 in BARD1 right now?

Before you consider BARD1, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and BARD1 wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!